Starpharma Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Starpharma Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	36.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Starpharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:SPL - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	10	-8	-7	-7	N/A
3/31/2024	10	-8	-7	-7	N/A
12/31/2023	11	-8	-7	-6	N/A
9/30/2023	7	-12	-10	-10	N/A
6/30/2023	4	-16	-15	-14	N/A
3/31/2023	5	-16	-12	-11	N/A
12/31/2022	5	-16	-8	-7	N/A
9/30/2022	5	-16	-11	-10	N/A
6/30/2022	5	-16	-14	-13	N/A
3/31/2022	5	-17	-18	-17	N/A
12/31/2021	4	-18	-21	-21	N/A
9/30/2021	4	-19	-18	-18	N/A
6/30/2021	3	-20	-15	-15	N/A
3/31/2021	3	-19	-13	-13	N/A
12/31/2020	3	-19	-11	-11	N/A
9/30/2020	5	-17	-11	-11	N/A
6/30/2020	7	-15	-11	-11	N/A
3/31/2020	7	-14	-10	-10	N/A
12/31/2019	8	-13	-8	-8	N/A
9/30/2019	5	-14	-10	-9	N/A
6/30/2019	3	-14	-11	-10	N/A
3/31/2019	4	-13	-9	-8	N/A
12/31/2018	4	-11	-7	-6	N/A
9/30/2018	5	-11	-9	-8	N/A
6/30/2018	5	-10	-11	-10	N/A
3/31/2018	5	-12	N/A	N/A	N/A
12/31/2017	4	-13	N/A	-18	N/A
9/30/2017	4	-14	N/A	-18	N/A
6/30/2017	4	-15	N/A	-17	N/A
12/31/2016	1	-20	N/A	-20	N/A
9/30/2016	3	-20	N/A	-19	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-22	N/A	-17	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	3	-20	N/A	-15	N/A
6/30/2015	2	-19	N/A	-14	N/A
3/31/2015	1	-18	N/A	-11	N/A
12/31/2014	1	-18	N/A	-9	N/A
9/30/2014	1	-16	N/A	-9	N/A
6/30/2014	1	-15	N/A	-10	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-9	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SPL's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if SPL's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if SPL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SPL's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if SPL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SPL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 23:02
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Starpharma Holdings Limited is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dennis Hulme	APP Securities Pty Ltd.
Tanushree Jain	Bell Potter
Matthijs Smith	Canaccord Genuity

Starpharma Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2022

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

Analysts lower revenue estimates to AU$9.89m

Price target raised to AU$1.73

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Releases New Data About SPL7013

Forecast to breakeven in 2022

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Starpharma Signs DEP ADC Research Agreement with MSD

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.80

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

New 90-day high: AU$1.68

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Analysts lower revenue estimates to AU$9.89m

Price target raised to AU$1.73

Earnings released

New 90-day high - AU$1.30